Melanoma | Norton Healthcare

Indication: Melanoma

Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV melanoma (DERM 20-91)

Sub-indication: Dermatologic Malignancies

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: BioNTech RNA Pharmaceuticals GmbH

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.